Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition

Por Fourneaux, Benjamin, Bourdon, Aurélien, Dadone, Bérengère, Lucchesi, Carlo, Daigle, Scott R., Richard, Elodie, Laroche-Clary, Audrey, Le Loarer, François, Italiano, Antoine
Publicado no J Hematol Oncol (2019)

Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition

Por Fourneaux, Benjamin, Bourdon, Aurélien, Dadone, Bérengère, Lucchesi, Carlo, Daigle, Scott R., Richard, Elodie, Laroche-Clary, Audrey, Le Loarer, François, Italiano, Antoine
Publicado no J Hematol Oncol (2019)

Abrogation of MLL-AF10 and CALM-AF10 mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l

Por Chen, Liying, Deshpande, Aniruddha, Banka, Deepti, Bernt, Kathrin M., Dias, Stuart, Buske, Christian, Olhava, Edward J., Daigle, Scott R., Richon, Victoria M., Pollock, Roy M., Armstrong, Scott A.
Publicado em 2012

MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition

Por Kühn, Michael W.M., Hadler, Michael J., Daigle, Scott R., Koche, Richard P., Krivtsov, Andrei V., Olhava, Edward J., Caligiuri, Michael A., Huang, Gang, Bradner, James E., Pollock, Roy M., Armstrong, Scott A.
Publicado no Haematologica (2015)

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l

Por Deshpande, Aniruddha J., Chen, Liying, Fazio, Maurizio, Sinha, Amit U., Bernt, Kathrin M., Banka, Deepti, Dias, Stuart, Chang, Jenny, Olhava, Edward J., Daigle, Scott R., Richon, Victoria M., Pollock, Roy M., Armstrong, Scott A.
Publicado em 2013

MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia

Por Riedel, Simone S., Haladyna, Jessica N., Bezzant, Matthew, Stevens, Brett, Pollyea, Daniel A., Sinha, Amit U., Armstrong, Scott A., Wei, Qi, Pollock, Roy M., Daigle, Scott R., Jordan, Craig T., Ernst, Patricia, Neff, Tobias, Bernt, Kathrin M.
Publicado no J Clin Invest (2016)

DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia

Por Rau, Rachel E., Rodriguez, Benjamin A., Luo, Min, Jeong, Mira, Rosen, Allison, Rogers, Jason H., Campbell, Carly T., Daigle, Scott R., Deng, Lishing, Song, Yongcheng, Sweet, Steve, Chevassut, Timothy, Andreeff, Michael, Kornblau, Steven M., Li, Wei, Goodell, Margaret A.
Publicado no Blood (2016)

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Por Daigle, Scott R., Olhava, Edward J., Therkelsen, Carly A., Basavapathruni, Aravind, Jin, Lei, Boriack-Sjodin, P. Ann, Allain, Christina J., Klaus, Christine R., Raimondi, Alejandra, Scott, Margaret Porter, Waters, Nigel J., Chesworth, Richard, Moyer, Mikel P., Copeland, Robert A., Richon, Victoria M., Pollock, Roy M.
Publicado em 2013

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Por Stein, Eytan M., Garcia-Manero, Guillermo, Rizzieri, David A., Tibes, Raoul, Berdeja, Jesus G., Savona, Michael R., Jongen-Lavrenic, Mojca, Altman, Jessica K., Thomson, Blythe, Blakemore, Stephen J., Daigle, Scott R., Waters, Nigel J., Suttle, A. Benjamin, Clawson, Alicia, Pollock, Roy, Krivtsov, Andrei, Armstrong, Scott A., DiMartino, Jorge, Hedrick, Eric, Löwenberg, Bob, Tallman, Martin S.
Publicado no Blood (2018)

Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor

Por Daigle, Scott R., Olhava, Edward J., Therkelsen, Carly A., Majer, Christina R., Sneeringer, Christopher J., Song, Jeffrey, Johnston, L. Danielle, Scott, Margaret Porter, Smith, Jesse J., Xiao, Yonghong, Jin, Lei, Kuntz, Kevin W., Chesworth, Richard, Moyer, Mikel P., Bernt, Kathrin M., Tseng, Jen-Chieh, Kung, Andrew L., Armstrong, Scott A., Copeland, Robert A., Richon, Victoria M., Pollock, Roy M.
Publicado em 2011